Back to journals
Academic Journal

MedRvix

17 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 17 psychedelic papers Blossom tracks from MedRvix line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does MedRvix carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

6papers published in 2023

+500% vs 2022

9 published by 2023

Browse papers→

Don't read as the journal's total output: only the 17 of 17 tracked psychedelic papers from MedRvix with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does MedRvix publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
11
Anxiety Disorders
7
Addiction & Substance Use
4
PTSD
4
Neuroimaging & Brain Measures
4
Safety & Risk Management
3
Veterans
3
Adolescents
3
Other
12

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does MedRvix cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
5
LSD
3
MDMA
2
DMT
2
Ketamine
2
Esketamine
1
Ayahuasca
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

MedRvix has 17 tracked papers indexed in Blossom (2021–2026) from 151 authors, most often covering Psilocybin, LSD and MDMA, across Depressive Disorders, Anxiety Disorders and Healthy Volunteers.

Published Papers

Open Accessindividual

Tripping on context: Characteristics and predictors of placebo and nocebo psychedelic effects

This pre-registered experiment (n=78) found that simply presenting inert air as nitrous oxide increased reported altered states of consciousness, ego dissolution, dissociation and side effects in healthy volunteers, although it did not change time perception. The placebo-like psychedelic effects were linked to greater responsiveness to verbal suggestion and absorption.

Published
Journal
MedRvix
Authors
Stein, M. V., Butler, M., Chapman, S., Deeley, Q., Terhune, D. B.
Open Accessindividual

Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study

This observational study (n=45) followed people with treatment-resistant depression receiving esketamine and found that psychedelic-like mystical experiences were common and varied widely between sessions. Higher mystical experience scores, especially positive mood and mystical feelings, were linked with greater improvement in depression symptoms, while dissociation was not.

Published
Journal
MedRvix
Authors
Mallevays, M., Fuet, L., Danon, M., Di Lodovico, L., Jaffré, C., Bouzeghoub, L., Mrad, S., Rousselet, A. V., Allary, L., Müh, C., Vissel, B., De Maricourt, P., Vinckier, F., Gaillard, R., Mekaoui, L., Gorwood, P., Petit, A. C., Berkovitch, L.
Open Accessmeta

A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

This living systematic review and meta-analysis (s=6) of randomised controlled trials (n=286) found that MDMA-assisted therapy was linked to greater short-term reductions in PTSD symptoms than control treatment, with higher response and remission rates. The overall certainty of the evidence was low, and the authors noted that the online resource will be updated as new trial data emerge.

Published
Journal
MedRvix
Authors
Sevchik, B. L., Singleton, S. P., Lahey, A., Cuijpers, P., Harrer, M., Jones, M. T., Nayak, S. M., Strain, E. C., Vandekar, S. N., Yaden, D. B., Dworkin, R. H., Scott, J. C., Satterthwaite, T. D.
Open Accessindividual

Molecular, haemodynamic, and functional effects of LSD in the human brain

Using simultaneous PET–MRI in healthy volunteers, this first integrated molecular and functional neuroimaging study quantifies LSD occupancy at cerebral serotonin 2A receptors and establishes a dose–occupancy relationship while revealing an anticlockwise hysteresis between plasma levels and subjective effects. LSD produced distinct haemodynamic and functional changes — increasing global cerebral and internal carotid artery flow without altering artery diameter and reducing global connectivity (GCOR), with GCOR changes negatively correlated with CBF and differing from effects of psilocybin — findings relevant to clinical development.

Published
Journal
MedRvix
Authors
McCulloch, D. E-W., Larsen, K., Johansen, A., Johansen, S. S., Jensen, P. S., Reveles Jensen, K. H., Holze, F., Falck, N., Neufeld, V., Steenstrup, E., Andersen, T. L., Skov-Andersen, P., Spanggård, A., Geisler, M., Randrup, P. P., Shulganov, V., Nielsen, M. K. K., Svarer, C., Fisher, P. M., Knudsen, G. M., Nykjær, C. H., Stenbæk, D. S.
Open Accessindividual

Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging

This preprint open-label study (n=20) examines the effects of ketamine infusions (35mg/70kg, 6x) on biological ageing markers in individuals with depression (MDD) or PTSD. It finds reductions in epigenetic age as measured by OMICmAge, GrimAge V2, and PhenoAge biomarkers, as well as significant changes in Epigenetic Biomarker Proxies (EBPs) and surrogate protein markers following a 2-3 week treatment course. The study also reports expected decreases in depression and PTSD scores as measured by PHQ-9 and PCL-5.

Published
Journal
MedRvix
Authors
Dawson, K., May, A., Carangan, J. M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B. C., Perkins, N., Mendez, T. L., Smith, R., Dawson, M., Mallin, M., Higgins-Chen, A. T., Dwaraka, V. B.
Open Accessindividual

Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors

In a sample of 863 regular meditators who had used psychedelics, 73.5% reported that psychedelic use positively influenced the quality of their meditation. Machine‑learning analyses (elastic net, random forest) identified greater frequency of psychedelic use, intentional set‑up for trips, higher agreeableness and reported N,N‑DMT exposure as the strongest predictors of perceiving such benefits, though causal claims require longitudinal or randomised studies.

Published
Journal
MedRvix
Authors
Jiwani, Z., Goldberg, S. B., Stroud, J., Young, J., Curtin, J., Dunne, J. D., Simonsson, O., Webb, C. A., Carhart-Harris, R., Schlosser, M.

Quick Facts

Papers Indexed
17
Publisher
Medvix Publications LLC
Website
Visit